Relay handed Lyrfigtu to Elevar for $5m upfront. FDA approval now tests the value of that unusual biotech deal
The FDA has approved Elevar Therapeutics’ Lyrfigtu for previously treated FGFR2-rearranged cholangiocarcinoma after a 46% response rate and 11.8-month median response duration. The drug enters an established targeted market, making FGFR2 selectivity, tolerability, molecular testing and eventual activity against resistance mutations more important than simply being another approved inhibitor.
